Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update

Silo Pharma, Inc. (NASDAQ:SILO) saw a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 82,948 shares, a decrease of 34.5% from the July 30th total of 126,549 shares. Based on an average daily volume of 81,506 shares, the days-to-cover ratio is currently 1.0 days. Approximately 5.4% of the shares of the company are sold short.

Institutional Investors Weigh In On Silo Pharma

A number of large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Silo Pharma by 134.6% in the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after acquiring an additional 53,309 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Silo Pharma during the 3rd quarter valued at approximately $74,000. DRW Securities LLC bought a new stake in shares of Silo Pharma during the 4th quarter valued at approximately $113,000. Finally, AdvisorShares Investments LLC increased its position in Silo Pharma by 64.3% during the 4th quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock worth $204,000 after purchasing an additional 234,629 shares in the last quarter. 5.58% of the stock is currently owned by institutional investors and hedge funds.

Silo Pharma Stock Performance

Shares of SILO stock traded up $0.01 during trading on Tuesday, hitting $2.48. The company had a trading volume of 3,575 shares, compared to its average volume of 199,017. The firm has a market capitalization of $3.95 million, a P/E ratio of -0.57 and a beta of 0.71. Silo Pharma has a one year low of $2.43 and a one year high of $15.15. The stock’s 50-day moving average price is $4.50 and its 200 day moving average price is $5.39.

Silo Pharma (NASDAQ:SILO) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.44). Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.